was identified with only one restriction endonuclease, BamHI, and although it represented less than the 50% of the DNA expected of a polymorphism, the band pattern was consistent with a previously reported allele polymorphism found in an estimated 2% of the population. 2 Third, the rearranged pattern was identified in a patient with a recent history of mixed chimerism for bone marrow engraftment.
The last point allowed definitive analysis of the patient specimen and provided an explanation of the GSH findings. The patient's pre-transplant bone marrow did not exhibit the altered BCR band. The healthy donor was not examined before transplant for a BCR gene rearrangement, in accordance with our clinical laboratory practice of providing costeffective testing. However, when assayed retrospectively for a BCR rearrangement, the donor exhibited the additional BamHI band pattern at the 50% level consistent with a constitutional polymorphism. Additionally, although it was not possible to determine the level of mixed chimerism present in the patient's bone marrow specimen obtained 120 days post-BMT, at 90 days there was 40-45% host (55-60% donor) present and the sample at 150 days was all donor. By extrapolation, the specimen at 120 days would have been approximately 80-90% donor. Since the donor had one normal and one polymorphic BCR allele, this level of mixed chimerism would account for the 40-45% apparent BCR rearrangement seen in the 120-day post-BMT sample. Thus, the results obtained for the BCR tumor marker combined with the presence of mixed chimerism are consistent with the absence of a BCR gene rearrangement in the patient's post-BMT specimen.
Although in this instance an alternative assay was available to provide a clear diagnosis and the BCR BamHI polymorphism had been previously reported, this is not true of all clinically relevant tumor markers. For example, MLL (11q23) rearrangements in acute leukemia can involve reciprocal translocations with at least 25 other chromosome regions 7 and Southern blot detection is often employed since a PCR-based assay might easily miss a gene rearrangement. Also, MLL polymorphisms have not been described. In conclusion, this novel case serves as an example of the possibility of misinterpreting Early detection of AML1/MTG8 fusion mRNA by RT-PCR in the bone marrow cells from a patient with isolated granulocytic sarcoma TO THE EDITOR Granulocytic sarcoma (GS) is an extramedullary tumor composed of immature granulocytes. GS usually develops as a precursor to blastic crisis in myeloproliferative and myelodysplastic syndromes or during the course of acute myelogenous leukemia (AML).
1,2 It is rarely recognized as an isolated tumor without any evidence of leukemia. In such cases, however, leukemia generally develops within a matter of months from the diagnosis of GS. 2 A close relationship between GS and gene abnormality was first reported by Swirsky et al; 3 subsequently, several karyotype abnormalities were demonstrated in GS patients. 4 In this report, we first demonstrated a chimeric gene transcript in the bone marrow cells in a patient with isolated GS. This case will help in understanding prognosis of such a patient.
A 22-year-old female was hospitalized in May 1996, due to numbness of her left foot for 3 months. Systemic computed tomography showed a giant intrapelvic mass (18 × 11 × 9 cm) with hydronephrosis of the left kidney due to obstruction of the left ureter by the tumor (Figure 1 ). Ga scintigraphy was positive at the tumor, but no other lesions were detected. Several examinations including peripheral blood count, bone marrow film, cerebrospinal fluid and karyotype analysis were normal. She was tentatively diagnosed as rhabdomyosarcoma, then, open biopsy was performed for differential diagnosis by using a standard panel of immunohistochemical antibodies. 5 Immunohistochemical features of the obtained specimen were as follows: DF-T1 (CD43), ++; LCA(CD45), ++/+; myeloperoxidase, ++; naphthol-ASD-chloroacetate esterase, +; LeuM1(CD15), −; UCHL-
Figure 1
Radiographic imaging of the tumor. Huge mass (18 × 11 × 9 cm) was detected in the left pelvic cavity of the patient by computed tomography. The tumor was well enhanced with some irregularly hypoenhanced lesions. Spinal involvement was not observed. There was no destructive lesion of the bones contacting the tumor (ishium, pelvis and acetabulum).
1(CD45RO), −; KP-1(CD68), −; L26(CD20), −; lysozyme, −; ␣1-antitrypsin, −; ␣1-antichymotrypsin, −; vimentin, −; cytokeratin, −; EMA, −; CEA, −; actin, −; desmin, −; S-100, −; NSE, −; chromogranin A, −. At this time, the patient was diagnosed as isolated GS. As stated previously, GS often occurs in CML 1 or AML, Gy delivered in 15 fractions) followed by a full-course of chemotherapy as for AML (JALSG AML89). No evidence of relapse was seen after the course of chemotherapy.
Recently, in the treatment of isolated GS, local therapy including surgical extirpation and/or irradiation followed by systemic chemotherapy has been proven to have an improved outcome. 6 Meis et al 2 showed that seven out of 13 patients with primary GS treated aggressively with systemic chemotherapy (54%) were free from leukemic manifestation with a maximum follow-up of 16 years. The review by Byrd et al 7 noted that 97% of patients with extramedullary leukemia (EML) treated only with local therapy developed AML at a median of 7 months. They also showed that 33% of patients with primary EML treated as AML ever developed AML. In this report, we demonstrate AML1/MTG8 fusion mRNA in the bone marrow cells of a patient with primary GS. Although the prognostic significance of GS with concomitant AML is sometimes controversial, GS is considered to be a poor risk for the favorable cytogenetic group of t(8;21). 8 Patients with t(8;21) AML and GS have shown a low CR rate and low overall survival. 8 To the best of our knowledge, however, there are no data about the therapeutic outcome of primary GS patient with the AML1/MTG8 fusion mRNA. Our case will be a good example in assessing prognosis of such a patient. RT-PCR gives us a useful tool in stratifying patients with primary GS towards consolidative therapy. This idea will be strengthened if the relationship between fusion mRNA in bone marrow cells and therapeutic outcome is clarified in previously reported cases. 
COMMENTS ON A PUBLISHED PAPER
Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia
TO THE EDITOR
Acute promyelocytic leukemia (APL) accounts for 5-10% of all acute myelogeneous leukemias (AML). APL is characterized by a maturation arrest of the leukemic cells at the promyelocytic stage, occurrence of coagulopathy, and the presence of a specific cytogenetic abnormality t(15;17) with the molecular rearrangement PML/RAR␣. Prognosis of APL has improved impressively due to the introduction of the differentiating agent all-trans retinoic acid (ATRA). With the combination of ATRA and chemotherapy, an improvement of complete remission (CR) rate and overall survival, and a reduction of early mortality and relapse rates have been observed in patients presenting either APL de novo, 1-3 resistant disease 4 or relapse. 5 We read with interest the article by Estey et al 6 concerning the association between increased body mass index (BMI) and APL in patients with AML. The authors' present data, obtained from 1245 patients with newly diagnosed AML of whom 120 had APL, showed an association between APL and obesity. 6 Although realized on a smaller series, a similar study carried out on our recent patients tends to confirm these results. The BMI, calculated as weight in kg/(height in meters) 2 and used as the measure of obesity, showed a mean value of 27.4 with a standard deviation of 4.3 (median value 26.1) in the last 27 APL patients (median age 43 years) seen in our institution, while BMI was 24.8 ± 3.7 (median value 24.6) in a cohort of 73 successive adult non-APL patients with AML (median age 66 years) corresponding to our patients included in the EORTC AML-10 and AML-13 protocols, and 23.1 ± 3.8 (median value 22.6) in a cohort of 45 successive adult patients with acute lymphoblastic leukemia (median age 42 years) corresponding to our patients included in the LALA-94 protocols for young and elderly adults. The higher mean value of BMI in APL patients comparatively to non-APL patients was confirmed when considering patients according to age (Figure 1 ) and sex (Figure 2 Drug doses used in the treatment of leukemia are usually calculated according to body-surface area and do not take into account the fat mass. Avoidance of drug toxicity is highly dependent on the schedule of drug administration and requires a choice in the duration of administration, frequency of repetition of the dose, and the sequencing of multiple drugs. Among the most widely used antineoplastic agents, the anthracycline antibiotics can cause a cardiac toxic reaction of great concern. Since the landmark paper of Bernard et al, 7 all main studies have incorporated anthracyclines as part of therapy in APL. With a standard schedule, cardiac toxicity develops as a result of cumulative injury to the myocardium, producing initial progressive disappearance of myofibrils from the cells to the late development of diffuse myocardial fibrosis. For daunorubicin, the most commonly used total dose limit is 900-1000 mg/m 2 . However, fatal congestive cardiomyopathies have been observed after a single dose, and congestive heart failure may occur many months after the discontinuation of anthracyclines.
Therefore, because of a risk of overdose chemotherapy, the wide use of cardiotoxic agents and the method of determining
Figure 1
Body mass index: comparison between leukemias according to age.
